E Fund Management’s Summit Therapeutics SMMT Stock Holding History

E Fund Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$444K	Sell	30,468 -281,357	-90%	-$4.99M	0.01%	305
2026 Q1	$5.91M	Buy	+311,825	New	+$5.04M	0.18%	75
2025 Q2	$472K	Sell	22,196 -273,421	-92%	-$6.24M	0.02%	236
2025 Q1	$5.7M	Sell	295,617 -682	-0.2%	-$13.7K	0.27%	57
2024 Q4	$5.29M	Buy	296,299 +15,194	+5%	+$295K	0.27%	50
2024 Q3	$6.16M	Buy	281,105 +271,029	+2,690%	+$3.79M	0.32%	30
2024 Q2	$78.6K	Sell	10,076 -20,653	-67%	-$112K	﹤0.01%	309
2024 Q1	$127K	Buy	+30,729	New	+$122K	0.01%	362

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

E Fund Management's SMMT Position: Q2 2026 in Review

E Fund Management reduced its Summit Therapeutics (SMMT) stake by 90% in Q2 2026, selling an estimated $4.99M and leaving 30,468 shares worth $444K. The position accounts for 0.01% of the portfolio, ranked #305.

E Fund Management first reported a position in SMMT in Q1 2024 and has held it in 8 quarters since. The position peaked at $6.16M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

E Fund Management held 30,468 shares of Summit Therapeutics worth $444K as of Q2 2026.
E Fund Management sold 281,357 Summit Therapeutics shares in Q2 2026, an estimated $4.99M.
Summit Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #305 holding.
E Fund Management first reported a position in Summit Therapeutics in Q1 2024 and has held it in 8 quarters since.
E Fund Management's Summit Therapeutics position peaked at $6.16M in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.